Bloomberg Law
June 29, 2020, 5:08 PM

AbbVie Combo Doesn’t Benefit Covid Patients, Study Finds (1)

John Lauerman
John Lauerman
Bloomberg News

A combination of antiviral drugs normally used to treat HIV didn’t benefit patients hospitalized for treatment of Covid-19, confirming earlier results that hadn’t been encouraging.

The two-drug treatment of lopinavir and ritonavir didn’t help patients survive infection with the coronavirus, when compared with usual care, according to researchers at the University of Oxford studying a variety of potential treatments. There was no evidence that the drugs, developed by Abbott Laboratories and sold by spinoff Abbvie Inc. as Kaletra, helped patients continue to breathe without assistance or recover more quickly.

Doctors are assessing a variety of drugs that have demonstrated a ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.